Literature DB >> 7927891

Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues.

J Kaczmarek1, P Castellani, G Nicolo, B Spina, G Allemanni, L Zardi.   

Abstract

Two different oncofetal fibronectins (FN) have been reported: one, generated by O-glycosylation in the splicing region IIICS that is recognized by monoclonal antibody (MAb) FDC-6, and another, recognized by MAb BC-I, generated by the alternative splicing of the FN pre-mRNA which includes an extra type-III repeat called ED-B. Using these and 2 other MAbs (IST-4 which recognizes all different FN isoforms and IST-6 which recognizes only the FN molecules that do not include the ED-B sequence) we have immunohistochemically studied 171 normal, hyperplastic and neoplastic breast-tissue specimens. Although all normal specimens reacted strongly with MAbs IST-4 and IST-6, they did not show the presence of oncofetal FNs as established by the use of BC-I and FDC-6. In contrast, out of the 97 cases of invasive ductal carcinomas studied, 90 (93%) and 96 (99%) reacted positively with BC-I and FDC-6, respectively, the reaction being observed in the tumoral stroma connective tissue and in tumoral vessels. Furthermore, invasive lobular carcinoma showed less intense and less frequent staining with BC-1 and FDC-6 (10 and 11 out of 14, respectively). We found differences in the distribution of the 2 oncofetal fibronectin isoforms within the same specimens. The most remarkable difference was observed in the tumoral vessels: in invasive ductal carcinoma MAb BC-1 revealed a positive reaction with vessels in 78% of cases while FDC-6 showed such a reaction in only 59% of cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927891     DOI: 10.1002/ijc.2910590104

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

Review 1.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

2.  Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.

Authors:  Zheng Han; Han Cheng; Jenny G Parvani; Zhuxian Zhou; Zheng-Rong Lu
Journal:  Magn Reson Med       Date:  2017-10-29       Impact factor: 4.668

3.  Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins.

Authors:  Elisa Ventura; Francesca Sassi; Sara Fossati; Arianna Parodi; William Blalock; Enrica Balza; Patrizia Castellani; Laura Borsi; Barbara Carnemolla; Luciano Zardi
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

4.  Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Authors:  Patrizia Castellani; Laura Borsi; Barbara Carnemolla; Attila Birò; Alessandra Dorcaratto; Giuseppe L Viale; Dario Neri; Luciano Zardi
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

5.  Topographical changes in extracellular matrix: Activation of TLR4 signaling and solid tumor progression.

Authors:  Rhiannon M Kelsh; Paula J McKeown-Longo
Journal:  Trends Cancer Res       Date:  2013-01-01

Review 6.  Fibronectins, their fibrillogenesis, and in vivo functions.

Authors:  Jean E Schwarzbauer; Douglas W DeSimone
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

Review 7.  Targeting tumor cell motility to prevent metastasis.

Authors:  Trenis D Palmer; William J Ashby; John D Lewis; Andries Zijlstra
Journal:  Adv Drug Deliv Rev       Date:  2011-06-02       Impact factor: 15.470

Review 8.  Interfering with pH regulation in tumours as a therapeutic strategy.

Authors:  Dario Neri; Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

Review 9.  Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Authors:  H Kosmehl; A Berndt; D Katenkamp
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

10.  Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme.

Authors:  Tone Sandal; Klara Valyi-Nagy; Virginia A Spencer; Robert Folberg; Mina J Bissell; Andrew J Maniotis
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.